RNAC

RNAC EBITDA Growth

-371.14%TTM

Period ending:

RNAC TTM EBITDA YoY %%
RNAC TTM EBITDA YoY %1163.65%-2646.80%
2016-12-312026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

RNAC ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 39 observations from Dec 31, 2016 to Jun 30, 2026.

Cartesian Therapeutics Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-371.1382%
-341.653%
-79.6857%
82.9379%
86.4295%
86.7544%
67.6702%
-721.6659%
-682.2286%
-2,278.0469%
-701.2945%
-169.6695%
-160.6446%
-123.7983%
794.8978%
236.6664%
224.2796%
167.3094%
91.5523%
48.4181%
37.8842%
-19.8521%
-28.681%
-23.4578%
-18.5688%
-0.5914%
17.7175%
22.1944%
14.7605%
7.8855%
0.7418%
-17.2143%
-30.8979%
-53.1751%
-85.4985%
-112.584%
-102.326%
-68.592%
-47.3341%

Compare ebitda growth

All RNAC financial metrics · RNAC stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.